August 1st, 2017 – Milan (Italy) and Kiev (Ukraine) - Axxam S.p.A. and Enamine Ltd. today announced the start of a Research Collaboration to enhance the Axxam small molecule screening library with the addition of a further set of compounds aimed at early-stage CNS drug discovery, achieving a total library size of ca. 280,000 compounds.
Over the course of the collaboration, Axxam and Enamine scientists will work together to apply a series of literature and proprietary chemoinformatics principles based on generating a highly diverse set of compounds with properties aimed at crossing the blood-brain barrier. Enamine will then provide these compounds, which will significantly augment the existing CNS compound collection at Axxam.
This is the latest phase of a long-standing relationship between the two companies that resulted in the construction of the current AXXDIV2.0 library at Axxam.